{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T03:08:12Z","timestamp":1789528092029,"version":"build-2803163510"},"reference-count":30,"publisher":"Impact Journals, LLC","issue":"18","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aging"],"published-print":{"date-parts":[[2021,9,30]]},"DOI":"10.18632\/aging.203534","type":"journal-article","created":{"date-parts":[[2021,9,18]],"date-time":"2021-09-18T22:07:35Z","timestamp":1632002855000},"page":"22286-22297","source":"Crossref","is-referenced-by-count":4,"title":["ASXL1 promotes adrenocortical carcinoma and is associated with chemoresistance to EDP regimen"],"prefix":"10.18632","volume":"13","author":[{"given":"Liang","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Urology, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinfeng","family":"Lyu","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunping","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenchen","family":"Feng","sequence":"additional","affiliation":[{"name":"Department of Urology, Huashan Hospital, Fudan University, Shanghai 200040, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Urology, Fourth Affiliated Hospital of China Medical University, Shenyang 100032, Liaoning Province, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2021,9,18]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"4172","DOI":"10.1038\/s41467-018-06366-z","article-title":"Metastatic adrenocortical carcinoma displays higher mutation rate and tumor heterogeneity than primary tumors.","volume":"9","author":"Kebebew","year":"2018","journal-title":"Nat Commun"},{"key":"2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.ejca.2009.12.007","article-title":"The European Network for the Study of Adrenal Tumors staging system is prognostically superior to the international union against cancer-staging system: a North American validation.","volume":"4","author":"Karakiewicz","year":"2010","journal-title":"Eur J Cancer"},{"key":"3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors.","volume":"17","author":"Terzolo","year":"2018","journal-title":"Eur J Endocrinol"},{"key":"4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/ng.2953","article-title":"Integrated genomic characterization of adrenocortical carcinoma.","volume":"4","author":"Kroiss","year":"2014","journal-title":"Nat Genet"},{"key":"5","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s00268-008-9521-0","article-title":"Candidate diagnostic markers and tumor suppressor genes for adrenocortical carcinoma by expression profile of genes on chromosome 11q13.","volume":"3","author":"Kebebew","year":"2008","journal-title":"World J Surg"},{"key":"6","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.mce.2013.10.028","article-title":"Genetics and epigenetics of adrenocortical tumors.","volume":"38","author":"Hammer","year":"2014","journal-title":"Mol Cell Endocrinol"},{"key":"7","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.ccell.2016.04.002","article-title":"Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.","volume":"2","author":"Morozova","year":"2016","journal-title":"Cancer Cell"},{"key":"8","doi-asserted-by":"publisher","first-page":"79292","DOI":"10.18632\/oncotarget.12685","article-title":"Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.","volume":"7","author":"Beuschlein","year":"2016","journal-title":"Oncotarget"},{"key":"9","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1530\/ERC-13-0439","article-title":"Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.","volume":"2","author":"Beuschlein","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"10","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1186\/s12885-019-6389-3","article-title":"Expression of FSCN1 and FOXM1 are associated with poor prognosis of adrenocortical carcinoma patients.","volume":"1","author":"Zhu","year":"2019","journal-title":"BMC Cancer"},{"key":"11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.ejmg.2015.10.007","article-title":"Penetrance of pathogenic mutations in haploinsufficient genes for intellectual disability and related disorders.","volume":"5","author":"Wienker","year":"2015","journal-title":"Eur J Med Genet"},{"key":"12","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1016\/j.jpedsurg.2007.12.022","article-title":"Outcome of adrenocortical tumors in children.","volume":"4","author":"Moir","year":"2008","journal-title":"J Pediatr Surg"},{"key":"13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0230-6","article-title":"The cancer driver genes IDH1\/2, JARID1C\/ KDM5C, and UTX\/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.","volume":"5","author":"Park","year":"2019","journal-title":"Exp Mol Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"221","DOI":"10.4103\/IJPM.IJPM_822_19","article-title":"Loss of ASXL1 expression is associated with lymph node metastasis in colorectal cancer.","volume":"6","author":"Lee","year":"2020","journal-title":"Indian J Pathol Microbiol"},{"key":"15","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1002\/ajh.26050","article-title":"Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.","volume":"9","author":"Tefferi","year":"2021","journal-title":"Am J Hematol"},{"key":"16","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma.","volume":"36","author":"Stepan","year":"2012","journal-title":"N Engl J Med"},{"key":"17","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3390\/biomedicines9020098","article-title":"The Role of Immunotherapy in the Treatment of Adrenocortical Carcinoma.","volume":"9","author":"Sworczak","year":"2021","journal-title":"Biomedicines"},{"key":"18","doi-asserted-by":"publisher","first-page":"101434","DOI":"10.1016\/j.beem.2020.101434","article-title":"Next-generation therapies for adrenocortical carcinoma.","volume":"3","author":"Fassnacht","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"19","doi-asserted-by":"publisher","first-page":"1901380","DOI":"10.1002\/advs.201901380","article-title":"Targeting YAP1\/LINC00152\/FSCN1 Signaling Axis Prevents the Progression of Colorectal Cancer.","volume":"7","author":"Ma","year":"2019","journal-title":"Adv Sci (Weinh)"},{"key":"20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12943-020-01221-6","article-title":"Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells.","volume":"1","author":"Jiang","year":"2020","journal-title":"Mol Cancer"},{"key":"21","doi-asserted-by":"publisher","first-page":"2265","DOI":"10.3892\/or.2020.7775","article-title":"N-Myc induces the tumor progression of prostate cancer by regulating FSCN1.","volume":"4","author":"Yin","year":"2020","journal-title":"Oncol Rep"},{"key":"22","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1530\/ERC-18-0500","article-title":"MDR1 inhibition increases sensitivity to doxorubicin and etoposide in adrenocortical cancer.","volume":"2","author":"Hofland","year":"2019","journal-title":"Endocr Relat Cancer"},{"key":"23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ijc.31296","article-title":"Targeting the multidrug transporter Patched potentiates chemotherapy efficiency on adrenocortical carcinomaand","volume":"14","author":"Mus-Veteau","year":"2018","journal-title":"Int J Cancer"},{"key":"24","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.2042-7158.2012.01606.x","article-title":"andevaluation of austocystin D liposomes.","volume":"6","author":"Gao","year":"2013","journal-title":"J Pharm Pharmacol"},{"key":"25","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1021\/np100429s","article-title":"The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes.","volume":"7","author":"Pelish","year":"2011","journal-title":"J Nat Prod"},{"key":"26","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity.","volume":"16","author":"Gelderblom","year":"2011","journal-title":"Eur J Endocrinol"},{"key":"27","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma.","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"key":"28","doi-asserted-by":"publisher","first-page":"22269","DOI":"10.1073\/pnas.1912700116","article-title":"Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.","volume":"11","author":"Fassnacht","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"29","doi-asserted-by":"publisher","first-page":"4654302","DOI":"10.1155\/2021\/4654302","article-title":"Identification of a Ferroptosis-Related Signature Associated with Prognosis and Immune Infiltration in Adrenocortical Carcinoma.","volume":"202","author":"Ma","year":"2021","journal-title":"Int J Endocrinol"},{"key":"30","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41419-020-2385-4","article-title":"Active steroid hormone synthesis renders adrenocortical cells highly susceptible to type II ferroptosis induction.","volume":"1","author":"Kroiss","year":"2020","journal-title":"Cell Death Dis"}],"container-title":["Aging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203534","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T15:44:34Z","timestamp":1633448674000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aging-us.com\/lookup\/doi\/10.18632\/aging.203534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,18]]},"references-count":30,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,9,30]]}},"alternative-id":["203534","34536950"],"URL":"https:\/\/doi.org\/10.18632\/aging.203534","relation":{},"ISSN":["1945-4589"],"issn-type":[{"value":"1945-4589","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,18]]}}}